REXULTI

When Otsuka America Pharmaceutical Inc.’s REXULTI, faced multiple FDA regulatory milestones in 2023, Coyne was critical in supporting the company and brand at each step. The team provided strategic counsel and created various materials for an FDA Advisory Committee meeting and the sNDA approval for the expanded use of Rexulti for the treatment of agitation associated with dementia due to Alzheimer's disease. Following approval, the team executed various media tactics, incorporating earned outreach and strategic sponsored content to get in front of HCP and patient audiences. Media efforts resulted in 366 placements and 908M+ impressions, including articles in Forbes, Reuters and US News & World Report.